1
|
Rolfo C, Arias D, Gandia JF, Manca P, Santos E, Raez LE. Ceritinib: an orphan drug for ALK positive non-small cell lung cancer with robust clinical evidence. Expert Opin Orphan Drugs 2017. [DOI: 10.1080/21678707.2017.1406347] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- Christian Rolfo
- Phase I - Early Clinical Trials Unit, Antwerp University Hospital & Center for Oncological Research (CORE), Edegem, Belgium
| | - David Arias
- Phase I - Early Clinical Trials Unit, Antwerp University Hospital & Center for Oncological Research (CORE), Edegem, Belgium
- Ourense University Hospital Complex, Ourense, Spain
| | - Jose Ferri Gandia
- Phase I - Early Clinical Trials Unit, Antwerp University Hospital & Center for Oncological Research (CORE), Edegem, Belgium
| | - Paolo Manca
- Phase I - Early Clinical Trials Unit, Antwerp University Hospital & Center for Oncological Research (CORE), Edegem, Belgium
- Medical Oncology Department, Campus Bio-Medico University, Rome, Italy
| | - Edgardo Santos
- Oncology Department, Lynn Cancer Institute, Boca Raton, FL, USA
| | - Luis E. Raez
- Thoracic Oncology Program, Memorial Cancer Institute, Memorial Health Care System, Pembroke Pines, FL, USA
| |
Collapse
|